1. Электронный научный архив УрФУ
  2. 00. Общеуниверситетские коллекции
  3. Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC
Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/111816
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorGusev, V. V.en
dc.contributor.authorLvova, O. A.en
dc.contributor.authorShamalov, N. A.en
dc.date.accessioned2022-05-12T08:23:37Z-
dc.date.available2022-05-12T08:23:37Z-
dc.date.issued2021-
dc.identifier.citationGusev V. V. Problems of Selecting an Anticoagulant for Secondary Stroke Prevention in Patients with Atrial Fibrillation / V. V. Gusev, O. A. Lvova, N. A. Shamalov. — DOI 10.1016/j.rinp.2021.104336 // Cardiovascular Therapy and Prevention (Russian Federation). — 2021. — Vol. 20. — Iss. 6. — P. 78-83. — 3044.en
dc.identifier.issn1728-8800-
dc.identifier.otherAll Open Access, Gold3
dc.identifier.urihttp://elar.urfu.ru/handle/10995/111816-
dc.description.abstractThe article describes the urgent problem of ischemic stroke prevention in patients with atrial fibrillation. It is proved that ischemic stroke in combination with AF is the most severe in terms of developing stable motor and speech disorders and disability. The frail older patients, as well as patients with swallowing disorders and reduced medical adherence present a special problem from this point of view. The most famous clinical studies on secondary prevention of cardioembolic stroke are RE-LY, ROCKET-AF, and ARISTOTLE. Based on subanalyses of randomized controlled trials, direct oral anticoagulants demonstrated a favorable efficacy profile in patients with atrial fibrillation and stroke/ transient ischemic attack, but the level of knowledge on each of them remained different. A number of advantages of rivaroxaban for primary and secondary prevention of stroke in patients with atrial fibrillation, including the elderly and patients with cognitive impairments and swallowing disorders, have been demonstrated. © 2021 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved.en
dc.description.sponsorshipRelationships and Activities. This publication was supported by AO Bayer (PPM_RIVRU00581).en
dc.format.mimetypeapplication/pdfen
dc.language.isoruen
dc.publisherSilicea-Poligrafen1
dc.publisherSilicea - Poligraf, LLCen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.sourceCardiovasc. Ther. Prev.2
dc.sourceCardiovascular Therapy and Prevention (Russian Federation)en
dc.subjectATRIAL FIBRILLATIONen
dc.subjectDIRECT ORAL ANTICOAGULANTSen
dc.subjectISCHEMIC STROKEen
dc.subjectSECONDARY PREVENTIONen
dc.subjectANTICOAGULANT AGENTen
dc.subjectRIVAROXABANen
dc.subjectARTICLEen
dc.subjectATRIAL FIBRILLATIONen
dc.subjectCARDIOEMBOLIC STROKEen
dc.subjectCOGNITIVE DEFECTen
dc.subjectDRUG EFFICACYen
dc.subjectDYSPHAGIAen
dc.subjectHUMANen
dc.subjectISCHEMIC STROKEen
dc.subjectMOTOR DYSFUNCTIONen
dc.subjectPROPHYLAXISen
dc.subjectRANDOMIZED CONTROLLED TRIAL (TOPIC)en
dc.subjectSPEECH DISORDERen
dc.subjectTRANSIENT ISCHEMIC ATTACKen
dc.titleProblems of Selecting an Anticoagulant for Secondary Stroke Prevention in Patients with Atrial Fibrillationen
dc.typeArticleen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeinfo:eu-repo/semantics/publishedVersionen
dc.identifier.rsi46668097-
dc.identifier.doi10.1016/j.rinp.2021.104336-
dc.identifier.scopus85118292019-
local.contributor.employeeGusev, V.V., Central City Clinical Hospital No 23, Yekaterinburg, Russian Federation, Ural Federal University Named after the First President of Russia B. N. Yeltsin, Yekaterinburg, Russian Federation, Ural State Medical University, Yekaterinburg, Russian Federation; Lvova, O.A., Ural Federal University Named after the First President of Russia B. N. Yeltsin, Yekaterinburg, Russian Federation, Ural State Medical University, Yekaterinburg, Russian Federation; Shamalov, N.A., Institute of Cerebrovascular Pathology and Stroke, Federal Center of Brain Research and Neurotechnologies, Moscow, Russian Federationen
local.description.firstpage78-
local.description.lastpage83-
local.issue6-
local.volume20-
local.contributor.departmentCentral City Clinical Hospital No 23, Yekaterinburg, Russian Federation; Ural Federal University Named after the First President of Russia B. N. Yeltsin, Yekaterinburg, Russian Federation; Ural State Medical University, Yekaterinburg, Russian Federation; Institute of Cerebrovascular Pathology and Stroke, Federal Center of Brain Research and Neurotechnologies, Moscow, Russian Federationen
local.identifier.pure23917728-
local.description.order3044-
local.identifier.eid2-s2.0-85118292019-
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85118292019.pdf175,57 kBAdobe PDFПросмотреть/Открыть
Показать базовое описание ресурса Статистика  Google Scholar





Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.